HK1210434A1 - Pharmaceutical formulation containing thienotriazolodiazepine compounds - Google Patents
Pharmaceutical formulation containing thienotriazolodiazepine compoundsInfo
- Publication number
- HK1210434A1 HK1210434A1 HK15111309.6A HK15111309A HK1210434A1 HK 1210434 A1 HK1210434 A1 HK 1210434A1 HK 15111309 A HK15111309 A HK 15111309A HK 1210434 A1 HK1210434 A1 HK 1210434A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical formulation
- formulation containing
- thienotriazolodiazepine compounds
- containing thienotriazolodiazepine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261707465P | 2012-09-28 | 2012-09-28 | |
US201361782882P | 2013-03-14 | 2013-03-14 | |
US201361831811P | 2013-06-06 | 2013-06-06 | |
PCT/IB2013/003026 WO2014068402A2 (fr) | 2012-09-28 | 2013-09-27 | Formulation pharmaceutique contenant des composés thienotriazolodiazepine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210434A1 true HK1210434A1 (en) | 2016-04-22 |
Family
ID=50475880
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111309.6A HK1210434A1 (en) | 2012-09-28 | 2015-11-17 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
HK15112002.4A HK1211209A1 (en) | 2012-09-28 | 2015-12-04 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112002.4A HK1211209A1 (en) | 2012-09-28 | 2015-12-04 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140107107A1 (fr) |
EP (1) | EP2900221B1 (fr) |
JP (1) | JP2015531365A (fr) |
KR (1) | KR20150100613A (fr) |
CN (1) | CN104968334B (fr) |
AU (1) | AU2013340483B2 (fr) |
BR (1) | BR112015006537A2 (fr) |
CA (1) | CA2885944A1 (fr) |
HK (2) | HK1210434A1 (fr) |
IN (1) | IN2015DN03135A (fr) |
MX (1) | MX2015003771A (fr) |
RU (1) | RU2015115634A (fr) |
WO (1) | WO2014068402A2 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011252808B2 (en) | 2010-05-14 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
WO2011143660A2 (fr) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes de traitement de la leucémie |
US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Betタンパク質阻害剤としての三環式複素環 |
ES2635560T3 (es) | 2013-07-08 | 2017-10-04 | Incyte Holdings Corporation | Heterociclos tricíclicos como inhibidores de la proteína NET |
WO2015014998A1 (fr) * | 2013-08-01 | 2015-02-05 | Oncoethix Sa | Préparation pharmaceutique contenant des composés de thiénotriazolodiazépine |
WO2015018520A1 (fr) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Inhibiteur bet-brd représentant un nouvel agent pour un lymphome anaplasique à grandes cellules alk positif |
EP3030242A1 (fr) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Procédé de traitement de lymphome diffus à grande cellules b (ldgcb) au moyen d'un inhibiteur de bromodomaine de bet |
WO2015018523A1 (fr) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Nouvel inhibiteur de bet-brd pour le traitement de tumeurs solides |
WO2015018522A1 (fr) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl) |
MX2016005980A (es) | 2013-11-08 | 2016-12-09 | Dana Farber Cancer Inst Inc | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. |
WO2015081189A1 (fr) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Hétérocycles bicycliques servant d'inhibiteurs des protéines bet |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
KR20160079823A (ko) * | 2013-11-27 | 2016-07-06 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 백혈병을 치료하는 방법 |
WO2015095492A1 (fr) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs des protéines bet |
EP3099693A4 (fr) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Utilisations des dérivés de diazépane |
JP2017504653A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアミノピリミジンベンゼンスルホン誘導体およびその使用 |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
MX2016011160A (es) | 2014-02-28 | 2017-04-27 | Tensha Therapeutics Inc | Tratamiento de afecciones asociadas con la hiperinsulinemia. |
ES2784846T3 (es) | 2014-04-23 | 2020-10-01 | Incyte Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET |
CA2947593A1 (fr) * | 2014-05-02 | 2015-11-05 | Oncoethix Gmbh | Methode de traitement de lymphome non hodgkinien resistant, de medulloblastome et/ou de cancer bronchopulmonaire non a petites cellules alk+ a l'aide de composes de thienotriazolodiazepine |
WO2015168587A1 (fr) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Procédé de traitement de myélome multiple résistant et de lymphome des cellules du manteau à l'aide de composés de thiénotriazolodiazépine |
RU2016146099A (ru) * | 2014-05-02 | 2018-06-05 | Онкоэтикс Гмбх | Способ лечения острого миелоидного лейкоза и/или острого лимфобластного лейкоза с помощью тиенотриазолодиазепиновых соединений |
WO2015169953A1 (fr) * | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine |
CA2947970A1 (fr) * | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Methode de traitement du cancer du sein triple negatif a l'aide de composes de thienotriazolodiazepine |
MX2016016388A (es) | 2014-06-13 | 2017-04-06 | Oncoethix Gmbh | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. |
CN107427524A (zh) * | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
EP3194406B8 (fr) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Composes triheterocycliques a utilisation comme inhibiteurs de proteine bet |
UA122130C2 (uk) * | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
WO2016176335A1 (fr) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Otx-015 deutéré |
JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
SG10202007090UA (en) | 2015-09-11 | 2020-08-28 | Dana Farber Cancer Inst Inc | Cyano thienotriazolodiazepines and uses thereof |
US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
BR112018009798A8 (pt) | 2015-11-25 | 2019-02-26 | Dana Farber Cancer Inst Inc | inibidores de bromodomínio bivalentes e usos dos mesmos |
WO2017106492A1 (fr) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinaisons pour le traitement du cancer |
EP3192502A1 (fr) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Composition pharmaceutique de selexipag |
WO2017121806A1 (fr) * | 2016-01-15 | 2017-07-20 | Sandoz Ag | Composition pharmaceutique de selexipag |
PE20240236A1 (es) | 2016-06-20 | 2024-02-16 | Incyte Corp | Formas solidas cristalinas de un inhibidor de bet |
CA3069339A1 (fr) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | Compositions pharmaceutiques contenant de l'entrectinib |
JP7311498B2 (ja) * | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
WO2019145410A1 (fr) | 2018-01-25 | 2019-08-01 | Boehringer Ingelheim International Gmbh | Traitement combiné de leucémie myéloïde aiguë |
MX2022003150A (es) * | 2019-09-18 | 2022-04-06 | Bristol Myers Squibb Co | Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2). |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022034914A1 (fr) * | 2020-08-13 | 2022-02-17 | カルナバイオサイエンス株式会社 | Préparation pharmaceutique solide facilement soluble et son procédé de production |
CN116098870B (zh) * | 2023-04-10 | 2023-07-25 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的固体分散体及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0989131T3 (da) * | 1996-09-13 | 2003-03-03 | Mitsubishi Pharma Corp | Thienotriazolodiazepinforbindelser og deres medicinske anvendelse |
CA2412776C (fr) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
CA2828610A1 (fr) * | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Formulations de dispersions solides et leurs procedes d'utilisation |
-
2013
- 2013-09-27 BR BR112015006537A patent/BR112015006537A2/pt not_active Application Discontinuation
- 2013-09-27 IN IN3135DEN2015 patent/IN2015DN03135A/en unknown
- 2013-09-27 CA CA2885944A patent/CA2885944A1/fr not_active Abandoned
- 2013-09-27 JP JP2015533717A patent/JP2015531365A/ja not_active Ceased
- 2013-09-27 WO PCT/IB2013/003026 patent/WO2014068402A2/fr active Application Filing
- 2013-09-27 MX MX2015003771A patent/MX2015003771A/es unknown
- 2013-09-27 CN CN201380061396.4A patent/CN104968334B/zh not_active Expired - Fee Related
- 2013-09-27 KR KR1020157009117A patent/KR20150100613A/ko not_active Application Discontinuation
- 2013-09-27 RU RU2015115634A patent/RU2015115634A/ru unknown
- 2013-09-27 AU AU2013340483A patent/AU2013340483B2/en not_active Ceased
- 2013-09-27 US US14/040,134 patent/US20140107107A1/en not_active Abandoned
- 2013-09-27 EP EP13848127.0A patent/EP2900221B1/fr not_active Not-in-force
-
2015
- 2015-11-17 HK HK15111309.6A patent/HK1210434A1/xx unknown
- 2015-12-04 HK HK15112002.4A patent/HK1211209A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013340483B2 (en) | 2018-01-18 |
JP2015531365A (ja) | 2015-11-02 |
IN2015DN03135A (fr) | 2015-10-02 |
CA2885944A1 (fr) | 2014-05-08 |
CN104968334B (zh) | 2018-09-14 |
KR20150100613A (ko) | 2015-09-02 |
US20140107107A1 (en) | 2014-04-17 |
EP2900221B1 (fr) | 2019-03-06 |
BR112015006537A2 (pt) | 2017-07-04 |
HK1211209A1 (en) | 2016-05-20 |
WO2014068402A2 (fr) | 2014-05-08 |
EP2900221A2 (fr) | 2015-08-05 |
MX2015003771A (es) | 2016-03-04 |
WO2014068402A3 (fr) | 2014-10-16 |
CN104968334A (zh) | 2015-10-07 |
RU2015115634A (ru) | 2016-11-20 |
AU2013340483A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211209A1 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
ZA201501930B (en) | Pharmaceutical composition | |
HK1203812A1 (en) | Novel pharmaceutical formulations | |
EP2931285A4 (fr) | Compositions pharmaceutiques | |
EP2832730A4 (fr) | Composition pharmaceutique contenant du mirabegron | |
HK1205146A1 (en) | Pharmaceutical formulation | |
GB201205164D0 (en) | Pharmaceutical compounds | |
HK1205683A1 (en) | Pharmaceutical formulation having improved stability | |
HK1216619A1 (zh) | 藥物化合物 | |
ZA201502987B (en) | Pharmaceutical composition | |
LT2638894T (lt) | Farmacinė kompozicija, turinti fosfolipido | |
RS59631B1 (sr) | Farmaceutska formulacija koja sadrži kurkumin | |
EP2897590A4 (fr) | Composition pharmaceutique | |
EP2883546A4 (fr) | Nouvelle composition pharmaceutique à libération différentielle contenant trois principes actifs | |
GB201202027D0 (en) | Pharmaceutical compounds | |
SG11201406097SA (en) | Capsule formulation | |
HK1204945A1 (en) | Pharmaceutical formulation containing flupirtin | |
HK1209339A1 (en) | Pharmaceutical formulations | |
EP2851078A4 (fr) | Composition pharmaceutique | |
GB201219236D0 (en) | Pharmaceutical compounds | |
GB201214121D0 (en) | Pharmaceutical compounds | |
GB201213519D0 (en) | Pharmaceutical compounds | |
GB201203253D0 (en) | Pharmaceutical compounds | |
ZA201400751B (en) | Pharmaceutical composition | |
GB201211406D0 (en) | Pharmaceutical formulations |